Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bart Neyns, Universitair Ziekenhuis Brussel
ClinicalTrials.gov Identifier:
NCT01066390
First received: January 8, 2010
Last updated: May 5, 2014
Last verified: August 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2014
  Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
No publications provided by Universitair Ziekenhuis Brussel

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):